

First PARP inhibitor approved in Egypt for patients with difficult-to-treat breast cancer, ovarian cancer

AstraZeneca Egypt has announced that Olaparib, a PARP inhibitor which works by stopping cancer cells from repairing themselves, has been approved in Egypt for multiple indications in metastatic breast cancer and advanced ovarian cancer.